Description:
Combimist-L Inhaler is a CFC-free combination inhalation therapy containing Levosalbutamol (a short-acting bronchodilator) and Ipratropium Bromide (an anticholinergic agent). It is used for the management of chronic obstructive pulmonary disease (COPD) and asthma, providing rapid and effective relief from symptoms such as wheezing, shortness of breath, chest tightness, and coughing. The CFC-free formulation is environmentally safe and ensures efficient drug delivery.
Therapeutic Uses:
Treatment and prevention of bronchospasm in COPD, chronic bronchitis, and emphysema
Adjunctive therapy in asthma when monotherapy is insufficient
Provides dual-action bronchodilation for improved respiratory function
Mechanism of Action:
Levosalbutamol is a beta-2 agonist that relaxes airway smooth muscles, offering quick relief from bronchospasm.
Ipratropium Bromide blocks muscarinic receptors in the lungs, reducing bronchoconstriction and airway secretions.
Together, they provide complementary bronchodilation for more effective symptom control.
Dosage Form:
Metered-Dose Inhaler (CFC-Free)
Prescription Status:
Prescription-only medication
Note:
Combimist-L Inhaler is intended for inhalation use only and should be used under medical supervision. It is not a replacement for long-term controller therapy in asthma. Patients should be instructed on proper inhalation technique for optimal therapeutic benefit.
Would you like this description formatted for product catalogs, packaging inserts, or online listings?
